AUTH:"De Placido S" - Search results

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Quaglino P, Lebbé C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzalez-Cao M, [...] Sileni VC

NEJM Evid, 3(10):EVIDoa2400087, 24 Sep 2024

Cited by: 0 articles | PMID: 39315864

Add to export list

Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.

Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, Cinieri S, Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D, Gennari A, Gori S, Grandi G, Guarneri V, Klinger M, Livi L, [...] De Laurentiis M

Cancer Treat Rev, 130:102815, 21 Aug 2024

Cited by: 0 articles | PMID: 39208751

Add to export list Review

Exploring the interplay between Kaposi's sarcoma and SARS-CoV-2 infection: A case series and systematic review.

Pietroluongo E, Luciano A, Peddio A, Buonaiuto R, Caltavituro A, Servetto A, De Angelis C, Arpino G, Palmieri G, Veneziani BM, De Placido S, Bianco R, De Placido P, Giuliano M

J Med Virol, 96(8):e29849, 01 Aug 2024

Cited by: 0 articles | PMID: 39135451

Add to export list Review

COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.

Pietroluongo E, Peddio A, De Placido P, Tortora M, Ottaviano M, Gelzo M, Cernera G, Foggia M, Buonomo AR, Pinchera B, Zappulo E, Mercinelli S, Cattaneo L, Sardanelli A, Viceconte G, Scotto R, Schiano Moriello N, Servetto A, De Angelis C, [...] Giuliano M

BMC Cancer, 24(1):748, 19 Jun 2024

Cited by: 0 articles | PMID: 38898390 | PMCID: PMC11188232

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.

Blondeaux E, Xie W, Carmisciano L, Mura S, Sanna V, De Laurentiis M, Caputo R, Turletti A, Durando A, De Placido S, De Angelis C, Bisagni G, Gasparini E, Rimanti A, Puglisi F, Mansutti M, Landucci E, Fabi A, Arecco L, [...] Regan MM

EClinicalMedicine, 70:102501, 20 Mar 2024

Cited by: 0 articles | PMID: 38685923 | PMCID: PMC11056413

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Machine Learning and Texture Analysis of [¹⁸F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients.

Hakkak Moghadam Torbati A, Pellegrino S, Fonti R, Morra R, De Placido S, Del Vecchio S

Biomedicines, 12(3):472, 20 Feb 2024

Cited by: 3 articles | PMID: 38540086 | PMCID: PMC10968471

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Coefficient of Variation in Metastatic Lymph Nodes Determined by <sup>18</sup>F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors.

Pellegrino S, Fonti R, Vallone C, Morra R, Matano E, De Placido S, Del Vecchio S

Cancers (Basel), 16(2):279, 09 Jan 2024

Cited by: 2 articles | PMID: 38254770 | PMCID: PMC10813913

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions.

Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C, De Placido S

Front Oncol, 14:1369562, 23 Jan 2024

Cited by: 0 articles | PMID: 38327748 | PMCID: PMC10848318

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, [...] Palmieri G

Nat Commun, 15(1):146, 02 Jan 2024

Cited by: 10 articles | PMID: 38167503 | PMCID: PMC10761671

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.

Cazzaniga ME, Pronzato P, Amoroso D, Bernardo A, Biganzoli L, Bisagni G, Blasi L, Bria E, Cognetti F, Crinò L, De Laurentiis M, Del Mastro L, De Placido S, Beano A, Ferraù F, Foladore S, Forcignanò R, Gamucci T, Garrone O, [...] Mustacchi G

Cancers (Basel), 16(1):117, 25 Dec 2023

Cited by: 0 articles | PMID: 38201545 | PMCID: PMC10777910

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Aromatase inhibitors: the journey from the state of the art to clinical open questions.

Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C, De Placido S

Front Oncol, 13:1249160, 22 Dec 2023

Cited by: 1 article | PMID: 38188305 | PMCID: PMC10770835

Add to export list Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, [...] LUCY investigators

Breast Cancer Res Treat, 204(2):237-248, 19 Dec 2023

Cited by: 4 articles | PMID: 38112922 | PMCID: PMC10948524

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.

Conte B, Boni L, Bisagni G, Durando A, Sanna G, Gori S, Garrone O, Tamberi S, De Placido S, Schettini F, Pazzola A, Ponzone R, Montemurro F, Lunardi G, Notaro R, De Angioletti M, Turletti A, Mansutti M, Puglisi F, [...] Del Mastro L

Clin Cancer Res, 29(24):5217-5226, 01 Dec 2023

Cited by: 0 articles | PMID: 37888299 | PMCID: PMC10722129

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.

Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L, Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano G

Cancer Treat Rev, 120:102618, 22 Aug 2023

Cited by: 2 articles | PMID: 37639757

Add to export list Review

Heterogeneity of Glycolytic Phenotype Determined by ¹⁸F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung Cancer.

Pellegrino S, Fonti R, Hakkak Moghadam Torbati A, Bologna R, Morra R, Damiano V, Matano E, De Placido S, Del Vecchio S

Diagnostics (Basel), 13(14):2448, 22 Jul 2023

Cited by: 3 articles | PMID: 37510192 | PMCID: PMC10378511

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors.

Pietroluongo E, De Placido P, Tortora M, Martinelli C, Viggiano A, Saponaro MR, Caltavituro A, Buonaiuto R, Morra R, Ottaviano M, Del Deo V, Cernera G, Gelzo M, Malfitano AM, Di Tolla MF, De Angelis C, Arpino G, Terracciano D, Bianco R, [...] Giuliano M

J Thorac Oncol, 18(10):1399-1407, 28 Jun 2023

Cited by: 3 articles | PMID: 37390981 | PMCID: PMC10303630

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511].

Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentiis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V

Cancer Treat Rev, 119:102594, 01 Jul 2023

Cited by: 0 articles | PMID: 37400291

Add to export list

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, [...] Prat A

NPJ Breast Cancer, 9(1):32, 29 Apr 2023

Cited by: 1 article | PMID: 37120452 | PMCID: PMC10148804

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: [email protected], Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Lancet, 401(10384):1277-1292, 01 Apr 2023

Cited by: 28 articles | PMID: 37061269

Add to export list

Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511].

Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentiis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V

Cancer Treat Rev, 117:102570, 05 May 2023

Cited by: 0 articles | PMID: 37150120

Add to export list

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.

Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentiis M, Fabi A, Rimanti A, Michelotti A, Mansutti M, Russo A, Montemurro F, Frassoldati A, Durando A, Gori S, Turletti A, Tamberi S, Urracci Y, Fregatti P, [...] Del Mastro L

EClinicalMedicine, 59:101931, 12 May 2023

Cited by: 3 articles | PMID: 37256095 | PMCID: PMC10225659

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.

Arpino G, de la Haba Rodríguez J, Ferrero JM, De Placido S, Osborne CK, Klingbiel D, Revelant V, Wohlfarth C, Poppe R, Rimawi MF, PERTAIN Study Group

Clin Cancer Res, 29(8):1468-1476, 01 Apr 2023

Cited by: 8 articles | PMID: 36716289 | PMCID: PMC10102835

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, [...] INOVATYON study group

Br J Cancer, 128(8):1503-1513, 09 Feb 2023

Cited by: 14 articles | PMID: 36759720 | PMCID: PMC10070417

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial.

Basile D, Rosati G, Bergamo F, Garattini SK, Banzi M, Zampino M, Bozzarelli S, Marchetti P, Galli F, Galli F, Longarini R, Zaniboni A, Ferrari D, De Placido S, Frassineti LG, Nicolini M, Cinieri S, Priscindiaro M, Ziranu P, [...] Aprile G

Clin Colorectal Cancer, 22(2):190-198, 05 Feb 2023

Cited by: 2 articles | PMID: 36935327

Add to export list

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype.

Caltavituro A, Buonaiuto R, Pietroluongo E, Morra R, Salomone F, De Placido P, Pagliuca M, Vaia A, Ottaviano M, Tortora M, De Placido S, Palmieri G, Giuliano M

Biomedicines, 11(3):874, 13 Mar 2023

Cited by: 1 article | PMID: 36979853 | PMCID: PMC10045500

Add to export list Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.

Exploring the interplay between Kaposi's sarcoma and SARS-CoV-2 infection: A case series and systematic review.

COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.

Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.

Machine Learning and Texture Analysis of [¹⁸F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients.

Coefficient of Variation in Metastatic Lymph Nodes Determined by <sup>18</sup>F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors.

Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions.

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.

Aromatase inhibitors: the journey from the state of the art to clinical open questions.

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.

Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.

Heterogeneity of Glycolytic Phenotype Determined by ¹⁸F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung Cancer.

Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors.

Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511].

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.

Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511].

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial.

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype.

Partnerships & funding